Literature DB >> 23830042

[An analysis of the diabetic population in a Spanish rural are: morbidity profile, use of resources, complications and metabolic control].

José M Inoriza1, Marc Pérez, Montse Cols, Inma Sánchez, Marc Carreras, Jordi Coderch.   

Abstract

OBJECTIVE: To describe the characteristics of a diabetic population, morbidity profile, resource consumption, complications and degree of metabolic control.
DESIGN: Cross-sectional study during 2010. LOCATION: Four Health Areas (91.301 people) where the integrated management organization Serveis de Salut integrated Baix Empordà completely provide healthcare assistance. PARTICIPANTS: 4.985 diabetic individuals, identified through clinical codes using the ICD-9-MC classification and the 3M? Clinical Risk Groups software. MAIN MEASUREMENTS: Morbidity profile, related complications and degree of metabolic control were obtained for the target diabetic population. We analyzed the consumption of healthcare resources, pharmaceutical and blood glucose reagent strips. All measurements obtained at individual level.
RESULTS: 99.3% of the diabetic population were attended at least once at a primary care center (14.9% of visits). 39.5% of primary care visits and less than 10% of the other scanned resources were related to the management of diabetes. The pharmaceutical expenditure was 25.4% of the population consumption (average cost ?1.014,57). 36.5% of diabetics consumed reagents strips (average cost ?120,65). The more frequent CRG are 5424-Diabetes (27%); 6144-Diabetes and Hypertension (25,5%) and 6143-Diabetes and Other Moderate Chronic Disease (17,2%). The degree of disease control is better in patients not consumers of antidiabetic drugs or treated with oral antidiabetic agents not secretagogues.
CONCLUSIONS: Comorbidity is decisive in the consumption of resources. Just a few part of this consumption is specifically related to the management of diabetes. Results obtained provide a whole population approach to the main existing studies in our national and regional context.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Keywords:  Comorbidity; Comorbilidad; Complicaciones de la diabetes; Diabetes complications; Diabetes mellitus; Glycosylated haemoglobin A; Health resources; Hemoglobina A glucosilada; Reagent strips; Recursos en salud; Tiras reactivas

Mesh:

Substances:

Year:  2013        PMID: 23830042     DOI: 10.1016/j.aprim.2013.04.007

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  5 in total

1.  Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data.

Authors:  Carla Sancho-Mestre; David Vivas-Consuelo; Luis Alvis-Estrada; Martin Romero; Ruth Usó-Talamantes; Vicent Caballer-Tarazona
Journal:  BMC Health Serv Res       Date:  2016-08-17       Impact factor: 2.655

2.  [Trends in the level of control of patients with type 2 diabetes from 2010 to 2015].

Authors:  Ana María Herrero Gil; Javier Pinillos Robles; Patricia Sabio Repiso; José Luis Martín Maldonado; Gerardo Garzón González; Ángel Gil de Miguel
Journal:  Aten Primaria       Date:  2017-08-21       Impact factor: 1.137

3.  [Morbidity observed in a health area: Impact on professionals and funding].

Authors:  Pablo de Miguel; Isabel Caballero; Francisco Javier Rivas; Jaime Manera; María Auxiliadora de Vicente; Ángel Gómez
Journal:  Aten Primaria       Date:  2014-10-23       Impact factor: 1.137

4.  Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain.

Authors:  Manel Mata-Cases; Marc Casajuana; Josep Franch-Nadal; Aina Casellas; Conxa Castell; Irene Vinagre; Dídac Mauricio; Bonaventura Bolíbar
Journal:  Eur J Health Econ       Date:  2015-11-05

5.  [Effectiveness and economic impact of a program of integrated care with telemedicine support on insulin-treated type 2 diabetic patients (Study GITDIABE)].

Authors:  Jose M Inoriza; Annabel Ibañez; Xavier Pérez-Berruezo; Cristina Inoriza-Nadal; Jordi Coderch
Journal:  Aten Primaria       Date:  2016-08-08       Impact factor: 1.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.